Chemotherapy can prolong survival in patients with advanced non-small-cell lung cancer--report of a Canadian multicenter randomized trial.
E Rapp, Joseph L. Pater, Andrew R. Willan et al. · Journal of Clinical Oncology · 1988
The survival benefit of combination chemotherapy to patients with advanced non-small-cell carcinoma of the lung (NSCLC) is controversial. To study this question, the National Cancer Institute of Canada (NCIC) Clinical Trials Group conducted a prospective randomized trial comparing best supportive care (BSC) to two chemotherapy regimens, vindesine and cisplatin (VP), and cyclophosphamide, doxorubicin, and cisplatin (CAP). Between February 1983 and January 1986, 23 centers across Canada entered 251 patients on study. Eighteen centers participated in the three-arm schema (150 patients); centers choosing not to participate in a study with a no-chemotherapy arm followed a two-arm schema comparing VP with CAP (101 additional patients). Altogether, 233 patients were eligible. Patients had measurable or evaluable disease, with either distant metastases (82.5%) or bulky limited disease considered inoperable or unsuitable for radical radiotherapy. The treatment groups were comparable in terms of age, sex, performance status, histology, disease extent, and weight loss. The overall response rates (complete response [CR] plus partial response [PR]) on the chemotherapy arms were CAP, 15.3%, and VP, 25.3% (P = .06). Patients on the three-arm portion of the trial had a median survival of 32.6 weeks when treated with VP, 24.7 weeks with CAP, and 17 weeks with BSC. The significance of the differences in survival, adjusted for prognostic factors, is as follows: chemotherapy v BSC, P = .02; VP v BSC, P = .01; and CAP v BSC, P = .05. Toxicity on the chemotherapy arms was significant, with leukopenia of severe or greater degree occurring in 37.8% (CAP) and 40.0% (VP), severe vomiting in 12.2% (CAP) and 23.3% (VP), and severe neurotoxicity in 15.6% (VP).
Cited by 698 works. doi:10.1200/jco.1988.6.4.633
Authors
- E Rapp
- Joseph L. Pater
- Andrew R. Willan
- Yvon F. Cormier
- Nevin Murray
- William Kenneth Evans
- D. Ian Hodson
- DavidA. Clark
- Ronald D. Feld
- Andrew Arnold
References
- Toxicity and response criteria of the Eastern Cooperative Oncology Group
- A New International Staging System for Lung Cancer
- A randomized trial of the four most active regimens for metastatic non-small-cell lung cancer.
- Cisplatin and Vindesine Combination Chemotherapy for Advanced Carcinoma of the Lung: A Randomized Trial Investigating Two Dosage Schedules
- The importance of dose intensity in chemotherapy of metastatic breast cancer.
- Commentary: current status of chemotherapy for non-small cell lung cancer.
- Benefits of polychemotherapy in advanced non-small-cell bronchogenic carcinoma
- COMPARISON OF TREATMENT POLICIES IN INOPERABLE BRONCHIAL CARCINOMA
- Random prospective study of vindesine versus vindesine plus high-dose cisplatin versus vindesine plus cisplatin plus mitomycin C in advanced non-small-cell lung cancer.
- Evaluation of response criteria in advanced lung cancer